(Q39325984)

English

Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.

scientific article

Statements

Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis. (English)
23 October 2013

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit